Suppliers of pharmaceutical intermediates are looking more at reducing cost and shortening time to market complex chemical compounds that are the building blocks used in producing active pharmaceutical ingredients (APIs). Faced with significant economic pressures as well as ever-increasing regulatory barriers, innovative drug companies look to industrial biotechnology companies as their suppliers and their processes as a source for high quality intermediates. As pharmaceutical manufacturers find their margins under pressure, they continue to look for ways to reduce cost through partnerships with industrial biotechnology companies. This session will focus on industrial biotechnology companies, providing lower cost sourcing through synthetic biology platforms for novel metabolic pathways to quality pharmaceutical intermediates that meet the same high level standards adhered to by their current commercial products.
Session ID: 0315183